CVRx achieved key foundational goals in 2025, with total revenue for Q4 2025 reaching $16.0 million, a 4% increase over the prior year quarter. The company also initiated the BENEFIT-HF trial and saw new Category I CPT codes take effect, positioning it for accelerated growth in 2026.
Total revenue for Q4 2025 was $16.0 million, an increase of 4% over the prior year quarter.
U.S. revenue for Q4 2025 was $14.9 million, also a 4% increase over the prior year quarter.
The company initiated the BENEFIT-HF trial, with first enrollments expected in Q2 2026, which could triple its addressable market.
Category I CPT codes and favorable physician fee payment levels became effective on January 1, 2026, removing automatic prior authorization denials.
For the full year of 2026, CVRx expects total revenue between $63.0 million and $67.0 million, gross margin between 84% and 86%, and operating expenses between $103.0 million and $107.0 million. For Q1 2026, total revenue is expected to be between $13.7 million and $14.7 million.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance